Regenique Group, which offers non-surgical aesthetic procedures in Singapore, filed on Friday with the SEC to raise up to $9 million in an initial public offering.
The Singapore-based company plans to raise $9 million by offering 2 million shares at a price range of $4 to $5. At the midpoint of the proposed range, Regenique Group would command a market cap of $167 million.
Regenique, through its subsidiary ClearSK, is an aesthetics services provider that operates five clinics across shopping, business and residential districts throughout Singapore, having served over 300,000 customers. The company offers approximately 100 non-surgical treatments divided into bio-regenerative therapies such as plant-based exosomes, stem-cell-derived skin boosters, and polynucleotide injectables, and medi-aesthetics solutions, including lasers, botulinum toxin (Botox), and energy-based body contouring. Clinics are staffed by licensed doctors to deliver anti-aging and longevity healthcare and aesthetic solutions.
Regenique Group was founded in 2009 and booked $11 million in revenue for the 12 months ended June 30, 2025. It plans to list on the Nasdaq under the symbol RGGG. Network 1 Financial Securities is the sole bookrunner on the deal.
